270 Chapter 11 Achkasov, S.I.; Tsukanov, A.S. Epithelial-mesenchymal transition and somatic alteration in colorectal cancer with and without peritoneal carcinomatosis. Biomed. Res. Int. 2014, 2014, 629496. https://doi.org/10.1155/2014/629496. [36] Sjo, O.H.; Berg, M.; Merok, M.A.; Kolberg, M.; Svindland, A.; Lothe, R.A.; Nesbakken, A. Peritoneal carcinomatosis of colon cancer origin: Highest incidence in women and in patients with right-sided tumors. J. Surg. Oncol. 2011, 104, 792–797. https://doi.org/10.1002/jso.21959. [37] Smith, C.G.; Fisher, D.; Claes, B.; Maughan, T.S.; Idziaszczyk, S.; Peuteman, G.; Harris, R.; James, M.D.; Meade, A.; Jasani, B.; et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin. Cancer Res. 2013, 19, 4104– 4113. https://doi.org/10.1158/1078-0432.Ccr12-2581. [38] Takahashi, Y.; Iwaya, T.; Sawada, G.; Kurashige, J.; Matsumura, T.; Uchi, R.; Ueo, H.; Takano, Y.; Eguchi, H.; Sudo, T.; et al. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Ann. Surg. Oncol. 2014, 21, 205–212. https://doi. org/10.1245/s10434-013-3264-3. [39] Taniguchi, H.; Uehara, K.; Nakayama, G.; Nakayama, H.; Aiba, T.; Hattori, N.; Kataoka, M.; Nakano, Y.; Kawase, Y.; Okochi, O.; et al. Tumor Location Is Associated With the Prevalence of Braf And PIK3CA Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl. Oncol. 2020, 13, 100786. https://doi. org/10.1016/j.tranon.2020.100786. [40] Yokota, T.; Ura, T.; Shibata, N.; Takahari, D.; Shitara, K.; Nomura, M.; Kondo, C.; Mizota, A.; Utsunomiya, S.; Muro, K.; et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer 2011, 104, 856–862. https://doi.org/10.1038/ bjc.2011.19. [41] Shirahata, A.; Sakata, M.; Sakuraba, K.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; Nemoto, H.; Sanada, Y.; et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 2009, 29, 279–281. [42] Shirahata, A.; Shinmura, K.; Kitamura, Y.; Sakuraba, K.; Yokomizo, K.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res. 2010, 30, 2689–2692. [43] Atreya, C.E.; Greene, C.; McWhirter, R.M.; Ikram, N.S.; Allen, I.E.; Van Loon, K.; Venook, A.P.; Yeh, B.M.; Behr, S.C. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J. Natl. Compr. Cancer Netw. 2016, 14, 1536–1543. https://doi.org/10.6004/jnccn.2016.0165. [44] Christensen, T.D.; Palshof, J.A.; Larsen, F.O.; Poulsen, T.S.; Høgdall, E.; Pfeiffer, P.; Jensen, B.V.; Yilmaz, M.K.; Nielsen, D. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncol. 2018, 57, 1057–1062. https://doi.org/10. 1080/0284186x.2018.1433322. [45] Prasanna, T.; Karapetis, C.S.; Roder, D.; Tie, J.; Padbury, R.; Price, T.; Wong, R.; Shapiro, J.; Nott, L.; Lee, M.; et al. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncol. 2018, 57, 1438–1444. https://doi.org/10.1080/028418 6x.2018.1487581. [46] Roberto, M.; Marchetti, P.; Arrivi, G.; Di Pietro, F.R.; Cascinu, S.; Gelsomino, F.; Caputo, F.; Cerma, K.; Ghidini, M.; Ratti, M.; et al. The treatment paradigm of right-sided metastatic colon cancer: Harboring BRAF mutation makes the difference. Int. J. Color. Dis. 2020, 35, 1513–1527. https://doi.org/10.1007/s00384-020-03589-9. [47] Schirripa, M.; Nappo, F.; Cremolini, C.; Salvatore, L.; Rossini, D.; Bensi, M.; Businello, G.; Pietrantonio, F.; Randon, G.; Fucà, G.; et al. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clin. Color. Cancer 2020, 19, 219–225. https://doi. org/10.1016/j.clcc.2020.04.009. [48] Tran, B.; Kopetz, S.; Tie, J.; Gibbs, P.; Jiang, Z.Q.; Lieu, C.H.; Agarwal, A.; Maru, D.M.; Sieber, O.; Desai, J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, 117, 4623–4632. https:// doi.org/10.1002/cncr.26086. [49] Yaeger, R.; Cercek, A.; Chou, J.F.; Sylvester, B.E.; Kemeny, N.E.; Hechtman, J.F.; Ladanyi, M.; Rosen, N.; Weiser, M.R.; Capanu, M.; et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014, 120, 2316–2324. https://doi.org/10.1002/cncr.28729. [50] Yang, Y.Z.; Hu, W.M.; Xia, L.P.; He, W.Z. Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer. Cancer Med.
RkJQdWJsaXNoZXIy MTk4NDMw